Palvella presents positive data for QTORIN rapamycin at vascular congress

Palvella Therapeutics (NASDAQ: PVLA) presented new clinical data from its Phase 3 SELVA and Phase 2 TOIVA studies at the International Society for the Study of Vascular Anomalies World Congress in Philadelphia. The data supports QTORIN rapamycin as a potential treatment for microcystic lymphatic malformations and cutaneous venous malformations.

In the SELVA Phase 3 study, all 13 participants aged 6-11 years showed improvement on the Microcystic Lymphatic Malformation Investigator Global Assessment scale at Week 24, with a mean improvement of +2.46 (p<0.001). Among participants with moderate or worse leaking/bleeding at baseline, 87% (20/23) showed improvement on the leaking/bleeding assessment, with a mean improvement of +2.48 (p<0.001).

All 43 participants who completed the efficacy evaluation period reported satisfaction with QTORIN rapamycin on the Treatment Satisfaction Questionnaire for Medication, with 84% reporting high levels of satisfaction. A blinded independent review demonstrated stability during the 8-week run-in period followed by improvement during treatment.

The TOIVA Phase 2 study for cutaneous venous malformations demonstrated statistically significant improvements in both height and appearance measures at all time points. At Week 24, the treatment showed a mean reduction of 1.50 points in height score and 1.43 points in appearance score (both p<0.001).

Palvella plans to submit a New Drug Application to the FDA for QTORIN rapamycin for microcystic lymphatic malformations in the second half of 2026. The company also plans to initiate a Phase 3 trial for cutaneous venous malformations in the second half of 2026. QTORIN rapamycin has received Breakthrough Therapy, Orphan Drug, and Fast Track designations from the FDA for microcystic lymphatic malformations.

You May Also Be Interested In

• FDA grants rolling review for Palvella's rapamycin NDA for rare condition
• SINTX Technologies receives $3.2M in ceramic manufacturing orders
• FDA grants breakthrough therapy status to Praxis drug for rare epilepsy